An international research team has harnessed sophisticated molecular tools and analysis methods to probe the underlying biology of the world’s most advanced malaria vaccine candidate — RTS,S — helping to explain how it protects against a disease that kills roughly half a million people each year, mostly infants and young children in Africa. The work, led by the Harvard T. H. Chan School of Public Health, the Broad Institute, the Fred Hutchinson Cancer Research Center, the University of Washington, and other leading institutions, was published online October 21 in The New England Journal of Medicine.
“Through this broad, multinational collaboration, we have brought the power of genomic tools to bear on a disease that poses one of the most significant threats to global public health,” said senior author Dr. Dyann Wirth, the Richard Pearson Strong Professor of Infectious Diseases and chair of the department of immunology and infectious diseases at the Harvard T. H. Chan School of Public Health. Wirth led theNEJM study together with Peter Gilbert of the Fred Hutchinson Cancer Research Center. Read more